JNJ
WAITJohnson & Johnson
$267.20
+0.33%delayed
News – · Trend ▼ · inside triggers –
Expected move (1d)
▼ $261.64to$272.76 ▲
ATR ±$5.56 (+2.08%)Implied ±$5.50 (+2.06%)
Entry Reference
Price / prev close$267.20 / $266.32
Day range$260.68 – $267.20
52-wk range$173.33 – $281.07(87%)
Volume vs avg0.69×
ATR (14d)$5.56
MA 8 / 21$270.41 / $269.30
MA 50 / 200$262.77 / $237.42
Call ▲ / Put ▼ trigger$267.63 / $265.01
+1 / +2 ATR$272.76 / $278.32
-1 / -2 ATR$261.64 / $256.08
Support: 263.83 250.44 247.21
Resistance: 269.43 274.90 276.47
Near-the-money contracts
exp 2026-09-18Calls
| Strike | Mark | IV | Δ | θ/day | OI |
|---|---|---|---|---|---|
| 260 | $7.23 | 45% | 0.77 | -0.61 | 5572 |
| 262.5 | $5.10 | 37% | 0.73 | -0.55 | 9 |
| 265 | $3.75 | 31% | 0.63 | -0.53 | 165 |
| 267.5 | $2.52 | 33% | 0.49 | -0.58 | 203 |
| 270 | $1.47 | 28% | 0.34 | -0.46 | 13259 |
| 272.5 | $0.80 | 30% | 0.22 | -0.40 | 655 |
Puts
| Strike | Mark | IV | Δ | θ/day | OI |
|---|---|---|---|---|---|
| 260 | $0.71 | 35% | -0.17 | -0.39 | 2830 |
| 262.5 | $1.04 | 33% | -0.25 | -0.46 | 407 |
| 265 | $1.86 | 32% | -0.37 | -0.52 | 2296 |
| 267.5 | $2.97 | 34% | -0.51 | -0.58 | 398 |
| 270 | $4.22 | 31% | -0.64 | -0.49 | 1247 |
| 272.5 | $6.72 | 50% | -0.67 | -0.77 | 343 |
Δ = delta (≈ probability ITM), θ/day = daily time decay, IV = implied vol. Greeks computed via Black-Scholes from Yahoo IV.
Recent news
- LEGN’s New CEO From Novartis Paves Way For Buyout Speculation3h ago
- Discover which dow jones stocks are making waves on Tuesday.7h ago
- Has BSX Stock Finally Hit Bottom?7h ago
- Johnson & Johnson Partner Contineum Slides as Depression Drug Fails11h ago
- Apollo and J&J Face a High-Stakes Orthopedics Deal12h ago
- Johnson & Johnson (JNJ) Is a Trending Stock: Facts to Know Before Betting on It13h ago
- 3 Dividend Stocks Baby Boomers Should Own for the Rest of Their Lives16h ago
- Cooper Companies: A Little More Compelling At This Price18h ago
- AI Safety Fears Drive Investors to J&J, Costco, and CrowdStrike for Cybersecurity22h ago
- SLS, IBRX, IOVA In Focus Amid Big Pharma’s Early Cancer-Asset Hunt: J&J Flags M&A ‘Sweet Spot,’ Pfizer Eyes Phase 1-2 Deals22h ago
- Reported Earlier, J&J's Subcutaneous RYBREVANT FASPRO Plus LAZCLUZE Shows Lower Rash, Administration-Related Reaction, Venous Thromboembolism Rates Than Intravenous MARIPOSA Regimen23h ago
- RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) plus LAZCLUZE® (lazertinib) with prophylactic strategies shows low rates of treatment-related events at WCLC 202623h ago
Reference data only. Not a recommendation. Greeks and expected-move figures are estimates, not certainties. You confirm all entries and contracts in TradingView and Charles Schwab.